Polycystic ovaries-beyond menopause

Climacteric

Volumn 17, Issue 2, 2014, Pages 109-115

  Shah, D ^a   Bansal, S ^a  

^a Gynaecworld   (India)

Author keywords

Cardiovascular; Menopause; Metabolic; Midlife; Risk

Indexed keywords

BIOLOGICAL MARKER;

ANOVULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE INFERTILITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MEDICAL HISTORY; MENOPAUSE; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOPHYSIOLOGY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN; COMPLICATION; FEMALE; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MENOPAUSE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 84896330413     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.828687     Document Type: Review

References (67)

1. Goodarzi M O, Dumesic D A, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011; 7: 219-31
2. Zawadski J, Dunaif AGJ. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif AGJ, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific publications, 1992: 377-84
3. Azziz R. P COS: a diagnostic challenge. Reprod Biomed Online 2004; 8: 644-8 (Pubitemid 38744941)
4. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88
5. Khan KA, Stas S, Kurukulasuriya LR. Polycystic ovarian syndrome. J Cardiometab Syndr 2006; 1: 125-30
6. Botwood N, Hamilton-Fairley D, Kiddy D, Robinson S, Franks S. Sex hormone-binding globulin and female reproductive function. J Steroid Biochem Mol Biol 1995; 53: 529-31
7. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 1996; 10: 221-4
8. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-5 (Pubitemid 39243189)
9. DeUgarte C M, Bartolucci A A, Azziz R, et al. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83: 1454-60 (Pubitemid 40615820)
10. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-63
11. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs 2002; 16: 17-23
12. Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts 2009; 2: 26-35
13. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006; 113: 1203-9 (Pubitemid 44401216)
14. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95: 1073-9 .e1-11
15. Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women ' s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97: 28-38 .e25
16. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32
17. Garcí a-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev 2006; 2: 39-49 (Pubitemid 44082949)
18. Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci 2011; 16: 763-9
19. Hudecova M, Holte J, Olovsson M, et al. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril 2011; 96: 1271-4
20. Ginsberg H N, MacCallum P R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic. I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009; 4: 113-19
21. Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril 2012; 97: 7-12
22. de Groot P C, Dekkers O M, Romijn J A, Dieben S W, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011; 17: 495-500
23. Soares GM, Vieira CS, Martins WP, et al. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol (Oxf) 2009; 71: 406-11
24. Davis S R, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric 2012; 15: 419-29
25. Tchernof A, Poehlman E T, Despré s J P. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 2000; 26: 12-20 (Pubitemid 30146088)
26. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopauserelated changes in body fat distribution. Ann N Y Acad Sci 2000; 904: 502-6 (Pubitemid 30389242)
27. Lovejoy J C. The menopause and obesity. Prim Care 2 003; 30: 317-25 (Pubitemid 36791420)
28. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 2008; 60: 10-18.
29. Dong M, Ren J. What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Curr Pharm Des 2013 May 14. Abstract 1. Epub ahead of print
30. Singh A K, Tiwari S, Gupta A, Natu S M, Mittal B, Pant AB. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord 2012; 10: 286-91
31. Izadi V, Farabad E, Azadbakht L. Epidemiologic evidence on serum adiponectin level and lipid profile. Int J Prev Med 2013; 4: 133-40
32. Lee S W, Jo H H, Kim M R, You Y O, Kim J H. Association between metabolic syndrome and serum leptin levels in postmenopausal women. J Obstet Gynaecol 2012;32: 73-7
33. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009; 15: 297-307
34. Krentz A J, von M ü hlen D, Barrett-Connor E. Adipocytokine profiles in a putative novel postmenopausal polycystic ovary syndrome (PCOS) phenotype parallel those in premenopausal PCOS: the Rancho Bernardo Study. Metabolism 2012; 61: 1238-41
35. Markopoulos M C, Valsamakis G, Kouskouni E, et al. Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. Eur J Endocrinol 2012; 168: 83-90
36. Chae CU, Derby CA. The menopausal transition and cardiovascular risk. Obstet Gynecol Clin North Am 2011; 38: 477-88
37. Matthews K A, Crawford S L, Chae C U, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009; 54: 2366-73
38. Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. Curr Hypertens Rep 2012; 14: 254-60
39. Do K A, Green A, Guthrie J R, Dudley E C, Burger H G, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol 2000; 151: 584-93 (Pubitemid 30463603)
40. Yanes L L, Reckelhoff J F. Postmenopausal hypertension. Am J Hypertens 2011; 24: 740-9
41. Kim C, Edelstein SL, Crandall JP, et al .; Diabetes Prevention Program Research Group. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause 2011; 18: 857-68
42. Kim C. Does menopause increase diabetes risk? Strategies for diabetes prevention in midlife women. Womens Health (Lond Engl) 2012; 8: 155-67
43. Polotsky H N, Polotsky A J. Metabolic implications of menopause. Semin Reprod Med 2010; 28: 426-34
44. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women ' s Health Across the Nation. Arch Intern Med 2008; 168: 1568-75
45. Moreau K L, Hildreth K L, Meditz A L, Deane K D, Kohrt W M. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab 2012; 97: 4692-700
46. Brown Z A, Louwers Y V, Fong S L, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril 2011; 96: 1259-65
47. Krentz AJ, von MD, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a doseeffect association with prevalent cardiovascular disease. Menopause 2007; 14: 284-92 (Pubitemid 46673480)
48. Shaw L J, Bairey Merz C N, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women ' s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-84
49. Rizzo M, Berneis K, Spinas G, Rini G B, Carmina E. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertil Steril 2009; 91(4 Suppl): 1563-7
50. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 2011; 96: 623-31
51. Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 2011; 96: 1827-34.
52. Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94: 1973-8
53. Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-termprospective study. Diabetes 2012; 61: 2369-74
54. Cobin R H. Polycystic ovarian syndrome and insulin resis - tance: implications for estrogen use in premenopausal and postmenopausal women. Metab Syndr Relat Disord 2005; 3: 259-69 (Pubitemid 41601244)
55. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96: 3794-803
56. Hudecova M, Jan H, Christian B, Poromaa Inger S. Long-term reproductive and metabolic consequences of PCOS. Curr Diabetes Rev 2012; 8: 444-51
57. Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in post-menopausal women - marker of the metabolic syndrome. Maturitas 2005; 50: 331-6 (Pubitemid 40365038)
58. Ireland K, Child T. Polycystic ovary syndrome and the postmenopausal woman. J Br Menopause Soc 2006; 12: 143-8 (Pubitemid 46017600)
59. Lambrinoudaki I. Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011; 68: 13-16
60. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-9 (Pubitemid 30192723)
61. Solomon C G, Hu F B, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87: 2013-17 (Pubitemid 34521483)
62. Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 2009; 12(Suppl 1): 22-5
63. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at longterm follow-up. J Clin Epidemiol 1998; 51: 581-6 (Pubitemid 28376967)
64. Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011; 17: 741-60
65. Murri M, Luque-Ramí rez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013; 19: 268-88
66. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009; 19: 398-405
67. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012; 27: 1327-31